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Summary
Animal agriculture is being transformed by rapid advances in biotechnology —
a term often used as a synonym for a variety of technologies that includes genetic
engineering, genetic modification, transgenics, recombinant DNA techniques, and
cloning, among others.  Producers are interested in the application of biotechnology
to improve productivity,  consistency, and quality; to introduce new food, fiber, and
medical products; and to protect the environment.  Potential human health
applications of transgenic animals include producing biopharmaceuticals and
generating organs, tissues, and cells for xenotransplantation. Criticisms of such
applications range from food safety and social resistance to potential negative
impacts on animal welfare and on ecosystems.  Questions also have arisen about the
adequacy of the current regulatory structure to manage the complex interaction
among environmental issues, public health, and food safety that developments in
animal biotechnology may create.
 The tools for introducing specific new genetic material into livestock have been
available since the mid-1980s.  However, few transgenic animal projects to date have
focused on actual agricultural issues such as animal health and production.  More
recently, however, cloned cattle capable of resisting mastitis are touted as a first
example of genetic engineering to improve animal well-being.  Pigs have been
engineered for increased sow milk production,  which has resulted in faster growing
piglets. Transgenic fish with enhanced growth characteristics are nearing the final
stages of commercialization. 
 In 2003, the U.S. Food and Drug Administration (FDA) released a draft risk
assessment stating that food products derived from cloned animals and their offspring
likely are as safe to eat as food from their non-cloned counterparts.  With that
statement,  the FDA also continued its voluntary moratorium request to companies
on sales of such food products.  It is anticipated that the FDA will issue its final risk
assessment report in 2006.  Since the cloning of the sheep, Dolly, in 1997,
Congressional concern with these advances has largely been confined to their
implications for human cloning.  However, Congress may be asked to play a larger
role in weighing the benefits and costs of these evolving technologies, and to refine
existing government oversight. 
 
This report will be updated as significant developments in agricultural
biotechnology occur and as Congress develops legislation addressing emerging
agricultural biotechnology issues.
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Biotechnology in Animal Agriculture: Status
and Current Issues
Introduction
  Biotechnology is a broadly defined term of relatively recent origin describing
the range of modern knowledge, applications, and techniques underlying advances
in many fields, notably health care and agriculture.  Animal biotechnology has been
defined as “that set of techniques by which living creatures are modified for the
benefit of humans and other animals.”1  By its very nature, agricultural development
is the history of humans modifying plants and animals to maximize desirable traits.
For example, domestication and selective breeding of animals date back many
thousands of years.  Artificial insemination of livestock, notably dairy cattle, is
another, more recent, biological technology, first finding wide commercial
acceptance in the 1950s.
 Discovery of the genetic code in the 1950s gave birth to modern techniques of
biotechnology.  One of the first commercial products of this new biotechnology in
animal agriculture was bovine somatotropin (bST).   BST is a naturally occurring
metabolic modifier that is now being manufactured in larger quantities through the
use of recombinant DNA technology.  Manufactured bST came onto the market in
1994 and is now administered to as many as half of all U.S. dairy cattle to increase
per-cow milk output.  Although bST is being used commercially in approximately
20 countries, it is banned in the European Union (EU).
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Other agricultural biotechnology developments include pigs that have been
engineered for increased sow milk output to produce faster growing piglets.  Cloned
cattle also have been developed to resist mastitis, and transgenic salmon with
enhanced growth characteristics are under regulatory consideration for possible
commercialization.  Output traits such as producing drugs recovered from animal
milk (“pharming”), making milk that lacks allergenic proteins, and producing animal
organs for human transplant that resist rejection (xenotransplantation) are other
contemporary objectives of animal biotechnology research.  In March 2006,
researchers at the University of Missouri announced the creation of transgenic pigs
whose tissue contains omega-3 fatty acids.2  The consumption of omega-3 fatty acids,
found primarily in fish,  has been linked to lowered incidence of heart disease in
humans.  Similar research is also under way to produce omega-3 fatty acids in cow’s
milk and in chicken eggs.    
This report describes several scientifically emerging animal biotechnologies
that, while not yet commercialized, are raising a variety of questions concerning risks
to humans and animals, the environment, and ethical issues pertaining to animal
welfare.  The report describes applications of the technologies and discusses major
issues that may arise.  Consumers, agricultural producers, the biotechnology industry,
and federal regulatory bodies are debating the relative costs and benefits of these
technologies.  As these technologies reach commercialization, Congress may be
asked to play an increasing role in weighing their costs and benefits and in refining
the current federal regulatory structure governing these technologies and their
agricultural products.  
 
Animal Biotechnologies
Given the breadth of the term “animal biotechnology,” one might reasonably
include thousands of years of humans selectively breeding animals as a
biotechnology: Observing desirable animal traits and attempting to breed those traits
into successive lines of animals.  Artificial insemination (AI) in the 1950s was a
technological advance in traditional selective breeding and an important adjunct to
the development of modern industrial animal production, especially in dairy and
poultry.  AI was adopted by producers and accepted by the public with virtually no
controversy.  Estrus synchronization, a related technology that improved the
efficiency of AI by more accurately controlling when a female was in heat, is also an
important animal biotechnology. With the development in the 1970s and patenting
in the 1980s of recombinant DNA techniques, and the subsequent analysis of genes,
their resulting proteins, and the role played by the proteins in animal biochemical
processes (functional genomics), modern biotechnology is increasingly equipped with
a set of sophisticated tools holding the promise of transforming the selective breeding
of animals.  The range of new techniques and technologies is only now beginning to
transform animal biotechnology in ways that plant biotechnology was transformed
in the 1980s and 1990s.   
Modern animal biotechnology is developing against the background of public
experience with plant biotechnology, and controversy over the technologies may be
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a continuing feature of animal biotechnology development, not least because of the
closer connection between humans and some animals and the belief that techniques
developed for animals are only a step away from application to humans.   Some of
the better known animal biotechnologies include: 
Embryo Transfer.  After AI and estrus synchronization, embryo transfer (ET)
is the third most commonly used biotechnology.  In ET, a donor cow of superior
breeding is chemically induced to superovulate.  The eggs are then fertilized within
the donor, the embryo develops and is then removed and implanted in a recipient
cow.  Between removal and implantation, embryos may be frozen for safekeeping.
Because of the relatively high costs, ET is used mostly within registered cowherds.
 
In Vitro Fertilization.  With in vitro fertilization (IVF), a technician removes
unfertilized eggs (oocytes) from the donor cow’s ovaries, usually recovering 6-8
useable oocytes.  The oocytes mature in an incubator and are fertilized with sperm.
The resulting zygotes incubate and develop in the laboratory before being placed into
the recipient cow.  While IVF can produce many fertilized embryos, the added
expense of ET makes the procedure prohibitive in most cases.  
Sexing Embryos.  The dairy industry prefers heifers and the beef industry
prefers bulls.  Embryo sexing methods in cattle have been developed using a bovine
Y-chromosome probe.  Technicians remove a few cells from the embryo and assess
the DNA in these cells for the presence of a Y-chromosome.   Presence of a Y-
chromosome determines the embryo is male.  Research is also developing in sperm
sexing technology.  
Transgenics.  A prominent area of contemporary animal biotechnology
research is the development of transgenic animals through genetic engineering (GE)
technology.3  Transgenic animals are produced by introducing an isolated DNA
fragment into an embryo so that the resulting animal will express a desired trait.4  The
only current routine use of transgenic animals, primarily mice, is in the area of human
disease research.  Potential agricultural applications for such genetic engineering,
however,  include improved feed use and faster growth; more resistance to disease;
meat that is leaner or that has more of some other desirable quality; and possibly even
animal waste that is more environmentally benign. Table 1 provides examples of
various objectives of animal biotechnology involving genetic modification.
Cloning.  Cloning is a biotechnology developing rapidly and with significant
public controversy.  Most people think of cloning as the creation of an organism that
is genetically identical to another one.  However, scientists use the term more
broadly, to refer to production not only of such organisms but also genetically
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identical cells, and to replication of DNA and other molecules.  It also refers to a
form of reproduction found naturally in many single-celled organisms, as well as
plants and animals.  Those differences in meaning and usage have caused some
confusion in public debate about cloning, where the main area of genuine controversy
relates to artificial cloning involving higher organisms, including humans.5  
Table 1. Agricultural Applications of Animal Genetic
Modification
 
Purpose Animal Model Transgenic Source















Swine Phytase gene; Bacteria
Increased wool production Sheep Cysteine synthesis gene:
Bacteria
Growth factor: Sheep










Source: GeneWatch UK, April 2002
a.  “Biosteel” is the trade name for spider web material intended to be produced in the milk of a
transgenic goat.  Said to be twenty times stronger than steel, “Biosteel” has an envisioned
breaking strength of about 300,000 pounds per square inch and could produce microscopically
fine, super strong fibers for industrial use.  
 In 1997, scientists at the Roslyn Institute in Scotland used nuclei from the
mammary cells of an adult sheep to clone “Dolly.”  Such nuclear transfer (NT)
techniques were first developed in amphibians in the 1950s.  They were first used in
sheep in 1986, with the production of clones using nuclei taken from sheep embryos.
The significance of “Dolly” was that she was cloned from differentiated cell types
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obtained from an adult (called “somatic cell NT”), rather than undifferentiated cells
from an embryo (“embryonic NT”). 
Although the success of animal cloning has raised the provocative issue of
human cloning, cloning in animal agriculture is generally not applied in isolation
from other biotechnologies such as genetic engineering.   The production of an NT
clone is a multi-step process that generates an entire organism from the DNA of a
single donor cell using NT.  Currently, NT is not a notably efficient technique that
would lead to widespread commercial adoption.   For example, only about 6% of the
embryos transferred to recipient cows result in healthy, long-term surviving clones.6
A more efficient cloning technology, one that can overcome the range of cloning
abnormalities that result from NT, however, may provide new opportunities in
human medicine, agriculture, and animal welfare.  This is the focus of much of the
current international animal biotechnology research.  
Regulation and Oversight
The basic federal guidance for regulating the products of agricultural
biotechnology is the Coordinated Framework for Regulation of Biotechnology (51
Fed. Reg. 23302), published in 1986 by the White House Office of Science and
Technology Policy (OSTP).  A key principle has been that GE products should
continue to be regulated according to their characteristics and unique features, not
methods of production, that is, whether or not they were created through
biotechnology.  The framework provides a regulatory approach intended to ensure
the safety of biotechnology research and products, using existing statutory authority
and previous policy experience.
Some newer applications of biotechnology did not exist when the current
regulatory framework was enunciated.  The NRC animal biotechnology report
concluded that this regulatory regime “might not be adequate to address unique
problems and characteristics associated with animal biotechnologies” and that federal
agency responsibilities are not clear.7
Food and Drug Administration (FDA).  Within the Department of Health
and Human Services (HHS), the FDA regulates food, animal feed ingredients, and
human and animal drugs, primarily under the Federal Food, Drug, and Cosmetic Act
(FFDCA; 21 U.S.C. §301 et seq.).  The FDA has stated that most — although
probably not all — gene-based modifications of animals for production or therapeutic
claims fall within the purview of the agency’s Center for Veterinary Medicine
(CVM), which regulates them under the FFDCA as new animal drugs.  A new animal
drug (NAD) must be approved by the agency after it is demonstrated to be safe to
man and animals, as well as being effective.  Regulation of transgenic animals as
NADs, however, suggests to some observers (e.g., the Center for Food Safety, Union
of Concerned Scientists) the inherent weakness of existing regulatory structures to
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respond adequately to the complexities that arise with animal biotechnology
innovations.8
Primarily under the FFDCA, FDA’s Center for Food Safety and Applied
Nutrition (CFSAN) is responsible for assuring that domestic and imported foods are
safe and properly labeled.  Generally, FDA does not review new foods themselves
for safety before they enter commerce but does have enforcement authority to act if
it finds foods that are adulterated under the act.  Also, all food additives, whether or
not introduced through biotechnology, must receive FDA safety approval before they
can be sold; the exception to pre-market approval are those on a list the FDA has
determined to be “generally recognized as safe” (GRAS).9
Sections of the FFDCA and of the Public Health Service Act (42 U.S.C. §262
et seq.) provide the authorities for FDA’s Center for Drug Evaluation and Research
and Center for Biologics Evaluation and Research to regulate the safety and
effectiveness of human drugs and other medical products, including those produced
by GM animals.  Under these laws, the FDA requires pre-market review and
licensing of such products, and requires that their production conditions ensure purity
and potency.10
U.S. Department of Agriculture (USDA).  Several USDA agencies,
operating under a number of statutory authorities, also have at least potential roles
in the regulation of transgenic and cloned animals and their products.  However, as
several critical reviews have indicated, USDA does not appear to have a clearly
spelled out policy in this area, including whether it intends to exercise these
authorities to regulate GE animals.11  The USDA’s Animal and Plant Health
Inspection Service (APHIS) has broad authority, under the Animal Health Protection
Act (AHPA; 7 U.S.C. §8301 et seq.) to regulate animals and their movement to
control the spread of diseases and pests to farm-raised animals.  APHIS also
administers the Viruses, Serums, Toxins, Antitoxins, and Analogous Products Act
(21 U.S.C. §151-159), aimed at assuring the safety and effectiveness of animal
vaccines and other biological products, including those of GM origin, and the Animal
Welfare Act (7 U.S.C. §2131 et seq.), portions of which govern the humane treatment
of several kinds of warm-blooded animals used in research (but generally not
agricultural animals).  Elsewhere at USDA, the Food Safety and Inspection Service
(FSIS) is responsible for ensuring the safety to humans of most food animals and
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meat and related products derived from them under the Federal Meat Inspection Act
(21 U.S.C. §601 et seq.) and Poultry Products Inspection Act (21 U.S.C. §451 et
seq.).
Reports and studies have cited a number of other authorities and federal
agencies that are or could be relevant.  The National Environmental Policy Act (42
U.S.C. §4321 et seq.) requires federal agencies to consider the environmental impacts
of their actions.  The Environmental Protection Agency derives its authority from,
among other laws, the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA;
21 U.S.C. §301 et seq.); pesticides derived from living organisms, including those
of biotechnology, are within its purview.  The Interior Department’s Fish and
Wildlife Service, and the Commerce Department’s National Marine Fisheries Service
have also been cited.
Policy Concerns
Environmental Issues.  Environmental concerns arising from emerging
animal biotechnologies are largely speculative at this time because few products have
been commercialized.  Industrial developers of agricultural biotechnology might
argue that more efficient production of animal-based feeds could reduce the resources
necessary to produce food and, thereby, reduce the environmental burden of animal
production.  Should the development and widespread adoption of the “EnviroPig”
(tm), which produces less phosphorus in its waste, occur, it might be considered by
some to be a positive environmental benefit of agricultural biotechnology.  
The 2002 NRC animal biotechnology report noted potential negative
environmental impacts of genetically altered animals.  Escape, survival, and gene
flow into wild populations were identified as major concerns.   Of most concern to
the NRC committee was the escape into the environment of “super” salmon that have
been genetically modified for rapid growth, and the likelihood that they could then
breed with wild populations in the environment.12  Other genetically altered animals
such as fish, insects, and shellfish could also potentially escape into natural
environments and become feral, disrupt ecosystems, or introduce novel genes in a
natural population.  
Food Safety.  Unexpected and unintended compositional changes arise with
all forms of plant and animal genetic modification, including GE, concluded the
IOM-NRC report on genetically engineered foods.13  The report added that, so far,
no GE-related adverse human health effects have been documented.  However, the
report’s authors cited “sizeable gaps” in the ability to identify compositional changes
caused by all forms of genetic modification — whether GE or conventional — and
their relevance for human health, and they recommended new approaches for
assessing the safety of new foods both before and after they enter the market.
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Previous research and experience with commercializing transgenic plants
suggest that negative effects on human health are virtually nonexistent.  While not
asserting that genetically modified organisms necessarily generate health problems,
more recently reported research in peer-reviewed scientific journals has suggested
that GMOs may raise food safety concerns: 
! Australian researchers have published an article explaining that the
transfer from a bean to a pea gene that expresses an insecticide
protein has resulted in  antibody production in mice fed the
transgenic pea. The antibody reaction is a marker of allergic
reaction.14
! Italian researchers at the University of Urbino had previously shown
that absorption of transgenic soy by mice induced modifications in
the nuclei of their liver cells. Recent research showed that a return
to non-transgenic soy made the observed differences disappear.15 
! Norwegian scientists at the University of Tromso demonstrated that
the catalyst 35S CaMV, an element of the genetic structures used to
modify a plant, can provoke gene expression in cultured human
cells.  This catalyst was previously believed to operate in this way
only in plants.16
In the NRC animal biotechnology report, experts observed that the scientific
principles for assessing the safety of GE animals are “qualitatively the same” as for
non-GE animals.17  However, because GE can introduce new proteins into foods, the
potential for allergenicity, bioactivity, and/or toxicity responses should be considered,
they said.  Others have remarked that animals genetically engineered for nonfood
products like pharmaceuticals or replacement organs might be of concern if such
animals entered or affected the food supply.18
Cloning.  The biotechnology industry so far has agreed not to market milk and
meat from cloned animals while it awaits FDA’s final risk assessment on the safety
of such products.  In an October 2003 draft risk assessment, the FDA had concluded
that “the current weight of evidence suggests that there are no biological reasons...to
indicate that consumption of edible products from clones of cattle, pigs, sheep or
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goats poses a greater risk than consumption of those products from their non-clone
counterparts.”19  However, shortly after its publication, many members of the FDA’s
Veterinary Medicine Advisory Committee stated that there were not enough data to
fully understand any potential risks from this relatively new techonology.20  Industry
officials assert that cloning will be used for breeding and that consumers will eat food
from the offspring of cloned individuals, rather than the cloned animals themselves.21
It is unknown whether this approach would eliminate risks, if any, associated with
ingestion of cloned animals.   
The NRC animal biotechnology report stated that embryonic splitting and
nuclear transfer using embryonic (not adult) cells were used with some dairy cows
to successfully produce genetically valuable offspring that were milked commercially
and whose milk and meat entered the food supply.  Few concerns were raised by
NRC authors about using these types of cloned animals for food, and they are
believed to pose a low level of food safety concern.  However, evaluating cloned-
animal food composition “would be prudent to minimize any food safety concerns.
The products of offspring of cloned animals were regarded as posing no food safety
concern because they are the result of natural matings.”22  Other issues, notably
consumer acceptance, social values, and animal welfare could eventually overshadow
any lingering questions about human health.
Consumer and Social Acceptance.   Criteria for selecting desirable traits
to be produced through transgenic animals will likely be based on the demand for
specific commercial characteristics.  Even if scientific evidence is convincing that
GE and cloned animal products are safe and beneficial for human consumption or
economically valuable to producers, other concerns may limit marketplace and
consumer acceptance.   Polls in recent years in the United States indicate that public
knowledge about food and biotechnology generally remains limited.  In two 2005
surveys, approximately half of those surveyed expressed opposition to the use of
biotechnology in the food supply.23  More than half of those in the Pew-sponsored
poll said they opposed research into genetically modified animals, although
opposition declined with increased knowledge.  Many Americans have heard about
animal cloning; two-thirds expressed discomfort with it — more of them out of
religious or ethical concerns than food safety concerns.  A majority of respondents
to the Pew survey believe that regulators should take into account ethical and moral
considerations. 
Consumers may be less willing to accept the practice of genetically modifying
animals than plants, some have argued, observing that people relate differently to
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animals, which many recognize as sentient beings.  Some observers have expressed
the concern that cloning farm animals might lead more quickly to human and pet
cloning, which those observers oppose.  Others believe that modifying animals, for
example, to save human lives through xenotransplantation or the production of some
important drug, might be more acceptable than doing so simply to produce more or
cheaper food.  Further, science alone cannot resolve ethical views which appear to
vary widely:
Some people, irrespective of the application of technology, consider genetic
engineering of animals fundamentally unethical.  Others, however, hold that the
ethical significance of animal biotechnologies must derive from the risk and
benefits to people, the animals, and/or the environment.  Yet another view
focuses on the right of humans to know what they are eating or how their food
or pharmaceuticals are being produced and therefore labeling becomes an issue
to be addressed.24
Such observations led some skeptics of animal biotechnology to propose that
the FDA not only consider the science and safety issues, but also these broader
concerns.  In the area of human reproductive health, for example, the FDA and other
federal agencies have invoked particular moral arguments either to reinforce
scientific arguments or to counterbalance scientific evidence. Others believe that the
FDA should base its decisions only on scientific evidence, and perhaps some other
body should be established to consider the ethical and cultural questions.  As the
NRC animal biotechnology report observed, regulatory decisions and enforcement
involving animal biotechnology “are difficult in the absence of an ethical
framework.”25
 
Some believe that segregating and labeling the products of biotechnology in
agriculture, including meat and milk, would enable the consumer to choose whether
or not to buy such products.  Both failing to segregate and label biotechnology
products as well as doing so can contribute to public suspicion that these products are
flawed or different in some negative way, which may lead to contradictory policy
decisions.26  Others counter that such products essentially are the same — and
subjected to the same rigorous safety standards — as more conventional products,
and therefore should be treated no differently in the marketplace.  Interestingly, a
study by USDA’s Economic Research Service reported that consumers’ willingness
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to pay for a food item declines when the food label indicates that it was produced
with the aid of biotechnology.27
Animal Welfare.  Some aspects of gene transfer have the potential to create
infectious disease hazards or impaired reproduction.  Looming large in the ethical
debate are questions about whether genetic modifications, cloning, and other
technologies, stress animals unnecessarily, subject them to higher rates of disease and
injury, and hasten death.28  The NRC animal agriculture report noted, for example,
that ruminants produced by in vitro culture or nuclear cell transfer methods tend to
have higher birth weights and longer gestation periods than those produced by
artificial insemination, creating potential calving problems.  Nuclear transfer
techniques to propagate genetic modifications may increase risks to the reproductive
health and welfare of both the surrogate female animals and their transgenic
offspring.  The report cited other evidence of problems such as anatomical,
physiological, or behavioral abnormalities in many transgenic animals.29  Some
scientists have countered that animal welfare problems have been exaggerated,
particularly as the technologies have advanced.  Most appear to agree, however, that
animals originating from some forms of genetic modification may require closer
observation and care.
International Trade Issues
Any exports of the products of animal biotechnology would presumably
encounter a wide spectrum of foreign regulatory regimes, some more restrictive than
the U.S. system.  For example, the current European Union restriction on new
biotechnology products is likely to encompass various restrictions on animal
biotechnology as it does on plant biotechnology.  International standards pertaining
to exports of animal products derived from biotechnology would have to be
developed.  The Codex Ad Hoc Intergovernmental Task Force on Foods Derived
from Biotechnology held its first meeting in September 2005 in Chiba, Japan, to
determine the new work projects for the four-year life of the task force.  Almost
every country, except for the United States, proposed an animal biotechnology
project.  The task force agreed to move forward with a recombinant DNA (r-DNA)
animal project, specifically to develop a guideline for how countries would assess the
safety of foods derived from r-DNA animals.30 
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safety standards for facilitating international trade of food products. The WTO cites Codex
texts as a benchmark in the Agreement on Sanitary and Phytosanitary Measures (SPS).
Congressional Activity
While Members of Congress have proposed various bills prohibiting human
cloning, no legislation is pending to address animal biotechnology issues directly.
With a forthcoming FDA risk assessment on the safety of the offspring of cloned
animals in the food supply, consumer and production issues may move to a more
prominent public position.  As with human cloning, ethical issues concerning animal
clones and other animal biotechnologies may also become more visible public issues.
Congress may be asked to play a larger role in weighing the benefits and costs of
these evolving technologies, and to refine existing government oversight.
